Edmonton, Canada

Atul Humar

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: University of Alberta. Active years: 2020.


% Patents Active = 100.0

 

Average Co-Inventor Count = 12.0

ph-index = 1


Company Filing History:


Years Active: 2020

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Atul Humar: Innovator in Immunomodulatory Peptides

Introduction

Atul Humar is a prominent inventor based in Edmonton, Canada. He has made significant contributions to the field of immunology through his innovative research and development of peptides that modulate immune responses. His work is particularly relevant in the context of enhancing immune function and developing therapeutic strategies.

Latest Patents

Atul Humar holds 1 patent for his invention titled "Immunomodulatory peptides and methods of use thereof." This patent provides a detailed disclosure of peptides that can modulate an immune response in individuals. The invention includes methods for modulating cellular responses in vitro and compositions that comprise these peptides. The applications of this patent are crucial for developing methods to enhance immune responses in individuals.

Career Highlights

Atul Humar is affiliated with the University of Alberta, where he conducts his research and development activities. His work at the university has positioned him as a key figure in the field of immunology, contributing to both academic knowledge and practical applications in healthcare.

Collaborations

Atul has collaborated with notable colleagues, including Bradley Scott Thomas and Khaled Hassan Sayed Barakat. These collaborations have further enriched his research and expanded the impact of his innovations in the scientific community.

Conclusion

Atul Humar's contributions to the field of immunology through his patented peptides demonstrate his commitment to advancing medical science. His work not only enhances our understanding of immune modulation but also paves the way for potential therapeutic applications.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…